Reuben S S, Connelly N R, Lurie S, Klatt M, Gibson C S
Department of Anesthesiology, Baystate Medical Center, Springfield, Massachusetts 01199, USA.
Anesth Analg. 1998 Jul;87(1):98-102. doi: 10.1097/00000539-199807000-00021.
This randomized, blind study was designed to determine the appropriate dose of ketorolac (a drug used as a supplement to opioids) to administer to patients who have undergone spinal stabilization surgery. The ketorolac was administered every 6 h, in addition to patient-controlled analgesia (PCA) with morphine, to 70 inpatients undergoing spine stabilization by one surgeon. The study was performed to determine the analgesic efficacy and incidence of side effects with different doses of ketorolac. The patients were divided into seven groups. They were given either i.v. saline (control group) or i.v. ketorolac (5, 7.5, 10, 12.5, 15, or 30 mg) every 6 h. The outcomes measured included pain scores, 24-h morphine usage, level of sedation, and side effect profile six times during the first 24 h postoperatively. The total dose of morphine was significantly larger in the control and 5 mg ketorolac groups than in the other five groups. Morphine consumption was similar in all groups receiving > or = 7.5 mg of ketorolac. The pain scores were significantly higher in the control group than in some of the larger dose groups at three of the study intervals. The 5 mg group had higher pain scores than the other groups at most of the time intervals studied. There were no significant differences in pain scores among the other five groups. Sedation scores were higher (i.e., patients were more sedated) in the control group than in the other six groups at three of the time periods. We conclude that the administration of ketorolac 7.5 mg every 6 h has a morphine-sparing effect equivalent to that of larger doses in patients undergoing spine stabilization surgery. Using larger doses of ketorolac did not result in less somnolence, lower morphine use, or less pain. We recommend that ketorolac 7.5 mg be given every 6 h to patients undergoing spinal fusion surgery in addition to PCA morphine.
Using smaller doses of ketorolac (e.g., 7.5 mg every 6 h) as a supplement to morphine patient-controlled analgesia is as effective as larger doses in patients who have undergone spine stabilization surgery.
本随机、盲法研究旨在确定酮咯酸(一种用作阿片类药物补充剂的药物)用于接受脊柱固定手术患者的合适剂量。除了采用吗啡进行患者自控镇痛(PCA)外,每6小时给70例由一名外科医生实施脊柱固定手术的住院患者使用一次酮咯酸。该研究旨在确定不同剂量酮咯酸的镇痛效果和副作用发生率。患者被分为七组。每6小时给他们静脉注射生理盐水(对照组)或静脉注射酮咯酸(5、7.5、10、12.5、15或30毫克)。测量的结果包括疼痛评分、24小时吗啡用量、镇静水平以及术后头24小时内六次的副作用情况。对照组和5毫克酮咯酸组的吗啡总用量显著高于其他五组。接受≥7.5毫克酮咯酸的所有组中吗啡消耗量相似。在三个研究时间段,对照组的疼痛评分显著高于一些较大剂量组。在大多数研究时间段,5毫克组的疼痛评分高于其他组。其他五组之间的疼痛评分无显著差异。在三个时间段,对照组的镇静评分高于其他六组(即患者镇静程度更高)。我们得出结论,对于接受脊柱固定手术的患者,每6小时给予7.5毫克酮咯酸具有与更大剂量相当的节省吗啡效果。使用更大剂量的酮咯酸并不会导致嗜睡减轻、吗啡用量降低或疼痛减轻。我们建议除PCA吗啡外,每6小时给接受脊柱融合手术的患者使用7.5毫克酮咯酸。
对于接受脊柱固定手术的患者,使用较小剂量的酮咯酸(如每6小时7.5毫克)作为吗啡患者自控镇痛的补充与较大剂量一样有效。